A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18

Tissue Antigens

Volumn 60, Issue 1, 2002, Pages 16-24

  Bilsborough, J ^a   Panichelli, C ^b   Duffour, M T ^c   Warnier, G ^b   Lurquin, C ^b   Schultz, E S ^d   Thielemans, K ^e   Corthals, J ^e   Boon, T ^b   Van Der Bruggen, P ^b  

^a AMGEN INC   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

HLA B18; HLA B44; MAGE 3; Peptide; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; HLA B ANTIGEN; HLA B18 ANTIGEN; HLA B44 ANTIGEN; MELANOMA ANTIGEN 3; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; HLA B18; HLA-B18; HLA-B44; MAGEA3 PROTEIN, HUMAN; TUMOR PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING COMPETITION; CANCER; CANCER IMMUNOTHERAPY; CELL CLONING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONE; CELL CULTURE; CHEMISTRY; DENDRITIC CELL; EPSTEIN BARR VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; CLONE CELLS; DENDRITIC CELLS; HERPESVIRUS 4, HUMAN; HLA-B ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 18644381320     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2002.600103.x     Document Type: Article

References (40)

1. Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994: 179: 921-30.
2. De Plaen E, Arden K, Traversari C et al. Structure, chromosomal localization and expression of twelve genes of the MAGE family. Immunogenetics 1994: 40: 360-9.
3. Lurquin C, De Smet C, Brasseur F et al. Two members of the human MAGEB gene family located in Xp.21.3 are expressed in tumors of various histological origins. Genomics 1997: 46: 397-408.
4. Lucas S, De Smet C, Arden KC et al. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res 1998: 58: 743-52.
5. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001: 61: 5544-51.
6. Boon T, Van den Eynde B. Cancer vaccines: Cancer antigens, shared tumor-specific antigens. In: Rosenberg SA, ed. Principles and Practice of the Biologic Therapy of Cancer. Philadelphia: JB Lippincott Williams & Wilkins, 2000: 493-504.
7. Tanzarella S, Russo V, Lionello I et al. Identification of a promiscuous T cell epitope encoded by multiple members of the MAGE family. Cancer Res 1999: 59: 2668-74.
8. Kawashima I, Hudson S, Tsai V et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998: 59: 1-14.
9. Tanaka F, Fujie T, Tahara K et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 1997: 57: 4465-8.
10. Oiso M, Eura M, Katsura F et al. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int J Cancer 1999: 81: 387-94.
11. Herman J, van der Bruggen P, Luescher I et al. A peptide encoded by the human gene MAGE-3 and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Immunogenetics 1996: 43: 377-83.
12. Schultz ES, Zhang Y, Knowles R et al. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens 2001: 57: 103-9.
13. Graham FL, Smiley J, Russel W, Nairu R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J General Virol 1977: 36: 59-72.
14. Parham P, Barnstable CJ, Bodmer WF. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C antigens. J Immunol 1979: 123: 342-9.
15. Van Snick J, Vink A, Cayphas S, Uyttenhove C. Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmocytomas. J Exp Med 1987: 165: 641-9.
16. Shimizu Y, DeMars R. Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J Immunol 1989: 142: 3320-8.
17. Rebai N, Malissen B. Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. Tissue Antigens 1983: 22: 107-17.
18. Strafford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread tong-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992: 90: 626-30.
19. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A 1995: 92: 6733-7.
20. Chaux P, Vantomme V, Stroobant V et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4 (+) T lymphocytes. J Exp Med 1999: 189: 767-77.
21. Sory MP, Cornelis GR. Translocation of a hybrid YopE-adenylate cyclase from Yersinia enterocolitica into HeLa cells. Mol Microbiol 1994: 14: 583-94.
22. Cornelis GR. The Yersinia deadly kiss. J Bacteriol 1998: 180: 5495-504.
23. Boland A, Cornelis GR. Role of YopP in suppression of tumor necrosis factor alpha release by macrophages during Yersinia infection. Infect Immun 1998: 66: 1878-84.
24. Neyt C, Iriarte M, Ha Thi V, Cornelis GR. Virulence and arsenic resistance in Yersiniae. J Bacteriol 1997: 179: 612-9.
25. Traversari C, van der Bruggen P, Van den Eynde B et al. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 1992: 35: 145-52.
26. Beyaert R, Vanhaesebroeck B, Suffys P, Van Roy F, Fiers W. Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo. Proc Natl Acad Sci U S A 1989: 86: 9494-8.
27. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Meth 1986: 95: 99-105.
28. Traversari C, van der Bruggen P, Luescher IF et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992: 176: 1453-7.
29. van der Bruggen P, Szikora J-P, Boël P et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol 1994: 24: 2134-40.
30. Chaux P, Luiten R, Demotte N et al. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 1999: 163: 2928-36.
31. Luiten R, van der Bruggen P. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. Tissue Antigens 2000: 55: 149-52.
32. Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. Adv Cancer Res 1995: 67: 155-95.
33. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance ans clinical relevance. Immunol Today 1995: 16: 487-94.
34. Herman J, Jongeneel V, Kuznetsov D, Coulie PG. Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid. Tissue Antigens 1999: 53: 111-21.
35. Tussey LG, Rowland-Jones S, Zheng TS et al. Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity 1995: 3: 65-77.
36. Marsh SGE, Parham P, Barber LD. The HLA Factsbook. London: Academic Press, 2000.
37. Voorter CE, van der Vlies S, Kik M, van den Berg-Loonen EM. Unexpected Bw4 and Bw6 reactivity patterns in new alleles. Tissue Antigens 2000: 56: 363-70.
38. Bourgault Villada I, Bénéton N, Bony C et al. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. Eur J Immunol 2000: 30: 2281-9.
39. Luiten RM, Demotte N, Tine J, van der Bruggen P. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens 2000: 56: 77-81.
40. Van den Eynde B, van der Bruggen P. Peptide database of T-cell defined tumor antigens. Cancer Immunity 2001: http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm.